HSBC Holdings
CYTK icon

HSBC Holdings’s Cytokinetics CYTK Stock Holding History

HSBC Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Buy
221,999
+218,303
+5,906% +$13.9M 0.01% 827
2025
Q4 		$235K Sell
3,696
-310
-8% -$19.3K ﹤0.01% 2625
2025
Q3 		$220K Buy
+4,006
New +$165K ﹤0.01% 2449
2023
Q4 		– Sell
-13,804
Closed -$414K – 2756
2023
Q3 		$414K Buy
+13,804
New +$460K ﹤0.01% 2062
2023
Q1 		– Sell
-17,734
Closed -$802K – 2755
2022
Q4 		$802K Buy
+17,734
New +$763K ﹤0.01% 2075
2022
Q2 		– Sell
-19,472
Closed -$727K – 3281
2022
Q1 		$727K Buy
19,472
+13,639
+234% +$485K ﹤0.01% 2158
2021
Q4 		$266K Buy
+5,833
New +$225K ﹤0.01% 2863

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HSBC Holdings's CYTK Position: Q1 2026 in Review

HSBC Holdings increased its Cytokinetics (CYTK) stake by 5,906% in Q1 2026, buying an estimated $13.9M and bringing the position to 221,999 shares worth $14.6M. The position accounts for 0.01% of the portfolio, ranked #827.

HSBC Holdings first reported a position in CYTK in Q4 2021 and has held it in 7 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • HSBC Holdings held 221,999 shares of Cytokinetics worth $14.6M as of Q1 2026.
  • HSBC Holdings bought 218,303 Cytokinetics shares in Q1 2026, an estimated $13.9M.
  • Cytokinetics made up 0.01% of HSBC Holdings's portfolio in Q1 2026, its #827 holding.
  • HSBC Holdings first reported a position in Cytokinetics in Q4 2021 and has held it in 7 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.